What Carbometrics does

Carbometrics is a Bristol, United Kingdom-based specialty chemistry and medical device company founded in 2018 that develops i-CAM, a continuous metabolic monitoring technology designed for use during cardiopulmonary bypass and organ perfusion procedures. The company is privately held, operates with a headcount in the 11-50 range, and positions itself at the intersection of chemistry-based sensing and clinical workflow applications in cardiac surgery and transplantation. Its core deliverable is a single product — i-CAM — described as the most comprehensive continuous metabolic monitor for cardiopulmonary bypass and organ perfusion circuits, with proprietary sensor technology as the principal differentiator relative to alternative monitoring approaches in this domain.

i-CAM is engineered to provide real-time metabolic monitoring throughout procedures such as open-heart surgery (where a heart-lung machine temporarily replaces cardiac and pulmonary function) and organ transplantation (where donor organs are preserved and transported on perfusion circuits). The technology is positioned as a domain-specialized solution rather than a general-purpose diagnostic platform, addressing a clinical gap in continuous metabolic visibility during these high-acuity procedures. No certifications, regulatory clearances, patents, or third-party validation are disclosed in the available material, indicating that i-CAM is likely still in development or pre-clinical validation stages.

The company's business model is currently oriented toward capital formation and partnership development rather than commercial sales. The company website explicitly states active outreach to clinical collaborators, OEM partners, and investors, and its only disclosed fundraising activity is approximately $2.5 million across two rounds in 2021 (led by SCVC, with Parkwalk Advisors, Ada Ventures, Selvedge Venture, and Télécom ParisTech participating). Pricing is not publicly disclosed, no distribution channels or named customers are listed, and the go-to-market motion appears to depend on OEM integration into larger medical device platforms paired with direct hospital engagement. Given this profile, the company is best characterized as pre-commercial, with revenue mechanics yet to be established.

Name

Carbometrics

Website

https://carbometrics.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Carbometrics is a Bristol, UK-based medical device company developing i-CAM, a continuous metabolic monitor engineered for cardiopulmonary bypass and organ perfusion circuits used in cardiac surgery and organ transplantation.

Ownership category

akta.pro rank

Product category

Medical Monitoring Equipment

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)

akta.pro secondary industries

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI), Ketone Monitoring (Blood/Urine) Devices & Strips (HLAHAHAI)

Keywords

• Continuous metabolic monitoring
• Cardiopulmonary bypass equipment
• Organ perfusion circuits
• Medical monitoring sensors
• Clinical chemistry devices

Headquarters

HQ city

Bristol

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations

Core offering

Carbometrics develops i-CAM, a continuous metabolic monitoring system designed for use during cardiopulmonary bypass and organ perfusion procedures. The device delivers real-time metabolic monitoring in surgical and transplant settings, providing clinicians with continuous insight into a patient's metabolic state during critical medical procedures. The company is engaged with clinical collaborators, OEM partners, and investors to advance the product.

Product overview

Carbometrics offers i-CAM, a single unified product serving as a comprehensive continuous metabolic monitoring solution specifically designed for cardiopulmonary bypass and organ perfusion circuits in medical settings.

Differentiator

Problem solved

Functional benefit

Products and services

• i-CAM

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves4 records

Expansion highlights3 records

Direct peers

• Abbott: Abbott's i-STAT system is the dominant point-of-care blood gas and metabolite analyzer used in operating rooms including during cardiac surgery. It is the closest direct analog in terms of metabolic-parameter measurement in perioperative settings and a logical competitor/partner for Carbometrics' i-CAM.
• OPTI Medical Systems: OPTI Medical manufactures point-of-care blood gas and metabolite analyzers (OPTI CCA-TS) used in operating rooms and critical care. It competes in the same intraoperative metabolic-monitoring space targeted by i-CAM.
• Nova Biomedical: Nova Biomedical manufactures Stat Profile and Prime Plus critical-care blood gas analyzers measuring glucose, lactate, and other metabolites at the point of care. Its products compete directly in the same perioperative metabolite-monitoring space as Carbometrics' i-CAM.
• Siemens Healthineers: Siemens Healthineers' RAPIDPoint blood gas analyzers provide critical-care metabolite measurements in surgical and ICU settings, directly comparable to the continuous metabolic monitoring Carbometrics targets with i-CAM.
• Werfen: Werfen's GEM Premier blood gas and metabolite analyzers are widely used in cardiac surgery and critical care, competing in the same intraoperative metabolic-monitoring category as Carbometrics' i-CAM.

Broad incumbents

• Medtronic: Medtronic has a broad cardiac surgery and patient-monitoring portfolio (including perfusion and biosensing) that is broadly comparable to where Carbometrics' technology would integrate. It represents a major incumbent competitor and potential strategic acquirer.
• LivaNova: LivaNova is a major manufacturer of cardiopulmonary bypass equipment and heart-lung machines, overlapping with Carbometrics' integration target. It is a logical OEM partner and potential acquirer for continuous metabolic monitoring capability within perfusion circuits.
• Edwards Lifesciences: Edwards Lifesciences is the established leader in hemodynamic monitoring (FloTrac, ClearSight, HemoSphere) in surgical and ICU settings. It is a relevant competitor in the operating-room monitoring space and a probable strategic acquirer of complementary monitoring technology.
• Masimo: Masimo is a leader in non-invasive patient monitoring technology (e.g., SET pulse oximetry) and has expanded into the operating room with multi-parameter monitoring. It is a broad incumbent competitor and convergence target for perioperative monitoring.
• Terumo Cardiovascular: Terumo Cardiovascular is the leading manufacturer of cardiopulmonary bypass systems — the exact circuits Carbometrics' i-CAM is designed to integrate with. As the dominant perfusion OEM, it is the most important commercial partner and a natural strategic acquirer of continuous metabolic monitoring capability.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/carbometrics
• LinkedInlinkedin.com/company/carbometrics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Carbometrics